DtJtBHxOCo
The manager
erectile dysfunction drugs buy comparison Drugmaker Retrophin Inc said it offered to buy therest of Transcept Pharmaceuticals shares it does not already ownfor $4 per share, valuing Transcept at about $75 million.Retrophin's offer represents an 11 percent premium toTranscept's closing share price of $3.59 on the Nasdaq onWednesday.
(Read comments)
Post a comment in response:
scribbld is part of the horse.13 network
Design by Jimmy B.
Logo created by hitsuzen.
Scribbld System Status